NCT06967272View on ClinicalTrials.gov

PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

June 15, 2026

Study Completion Date

November 15, 2026

Conditions
Rotavirus Gastroenteritis
Interventions
BIOLOGICAL

Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavirus attenuated live vaccine (low-dose) three doses administered orally

BIOLOGICAL

Oral hexavalent reassortant rotavirus attenuated live vaccine

Oral hexavalent reassortant rotavirus attenuated live vaccine (high-dose) three doses administered orally

BIOLOGICAL

Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)

The controlled vaccine three doses administered orally

Trial Locations (1)

430079

RECRUITING

Hubei Provincial Center for Disease Control and Prevention, Wuhan

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY